Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review

References

• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
   PubMed Web of Science ®Google Scholar
• Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19(7):953–964.
   PubMed Web of Science ®Google Scholar
• George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371(7):654–666.
   PubMed Web of Science ®Google Scholar
• Nguyen MN, Nayernama A, Jones SC, et al. Proteasome inhibitor-associated thrombotic microangiopathy: a review of cases reported to the FDA adverse event reporting system and published in the literature. Am J Hematol. 2020;95(9):E218–E222.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186–197.
   PubMed Web of Science ®Google Scholar
• Fotiou D, Roussou M, Gakiopoulou C, et al. Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. Blood Cancer J. 2020;10(11):109.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Cuadrado M, Phillips E, et al. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. Br J Haematol. 2021;193(4):750–760.
   PubMed Web of Science ®Google Scholar
• Monteith B, Venner C, Reece D, et al. Unusual carfilzomib toxicity: three cases of drug-induced thrombotic microangiopathy (TMA) after treatment with high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone (wCCD). Clin Lymphoma Myeloma Leuk. 2019;19(10):e272–e273.
   Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood. 2011;118(17):4519–4529.
   PubMed Web of Science ®Google Scholar
• Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med. 2013;368(23):2169–2181.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Palmieri S, Rocco S, Vitagliano O, et al. KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients. Ann Hematol. 2020;99(12):2903–2909.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park Y, Kang KW, et al. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. Ann Hematol. 2021;100(8):2051–2059.
   PubMed Web of Science ®Google Scholar
• Rocchi S, Tacchetti P, Pantani L, et al. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. Hematol Oncol. 2021;39(1):41–50.
   PubMed Web of Science ®Google Scholar
• Das DS, Ray A, Song Y, et al. Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. Br J Haematol. 2015;171(5):798–812.
   PubMed Web of Science ®Google Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22–32.
   PubMed Web of Science ®Google Scholar
• Elessa D, Talbot A, Lombion N, et al. Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature. Br J Haematol. 2020;188(2):338–340.
   PubMed Web of Science ®Google Scholar
• Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358(11):1129–1136.
   PubMed Web of Science ®Google Scholar
• Yui JC, Garceau D, Jhaveri KD, et al. Monoclonal gammopathy-associated thrombotic microangiopathy. Am J Hematol. 2019;94(10):E250–E253.
   PubMed Web of Science ®Google Scholar
• Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Ggroup. Nat Rev Nephrol. 2019;15(1):45–59.
   PubMed Web of Science ®Google Scholar
• Blasco M, Martínez-Roca A, Rodríguez-Lobato LG, et al. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol. 2021;193(1):181–187.
   PubMed Web of Science ®Google Scholar
• Rassner M, Baur R, Wäsch R, et al. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with eculizumab in multiple myeloma. BMC Nephrol. 2021;22(1):32.
   PubMed Web of Science ®Google Scholar
• Portuguese AJ, Lipe B. Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion. Blood Adv. 2018;2(23):3443–3446.
   PubMed Web of Science ®Google Scholar
• Bhutani D, Assal A, Mapara MY, et al. Case report: carfilzomib-induced thrombotic microangiopathy with complement activation treated successfully with eculizumab. Clin Lymphoma Myeloma Leuk. 2020;20(4):e155–e157.
   PubMed Web of Science ®Google Scholar
• Yan Y, Qin X, Liu J, et al. Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level by QM-FISH. Blood Adv. 2022;6(2):441–451.
   PubMed Web of Science ®Google Scholar
• Chen Y, Ooi M, Lim SF, et al. Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Blood Cancer J. 2016;6(7):e450.
   PubMedGoogle Scholar
• Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. 2016;91(9):E348–E352.
   PubMed Web of Science ®Google Scholar
• Jindal N, Jandial A, Jain A, et al. Carfilzomib-induced thrombotic microangiopathy: a case based review. Hematol Oncol Stem Cell Ther. 2020;S1658-3879:30118-7. Doi: https://doi.org/10.1016/j.hemonc.2020.07.001
   Google Scholar
• Monteith BE, Venner CP, Reece DE, et al. Drug-induced thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma: a case series and review of the literature. Clin Lymphoma Myeloma Leuk. 2020;20(11):e791–e800.
   PubMed Web of Science ®Google Scholar